RxDoctor Payments Data

Naga Lakshmana Nidadavolu, MD

Neuromuscular Medicine · Saint Cloud, FLNPI 1386835601

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 529 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,909, 5.5 times the $344 reported in 2019.

$8,694in general payments, 2019–2025

Across 529 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Bristol Myers Squibb$698
  • Novartis$457
  • UCB, Inc.$388
  • Lilly USA, LLC$357
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$834,102
Medicare patients
1,362
Services billed
5,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate414$667,630
QuliptaAtogepant500$593,675
UbrelvyUbrogepant397$555,041
Emgality PenGalcanezumab-Gnlm393$321,734
Aimovig AutoinjectorErenumab-Aooe251$228,003
RexultiBrexpiprazole104$194,299
IngrezzaValbenazine Tosylate17$186,257
HizentraImmun Glob G(Igg)/Pro/Iga 0-5024$123,584
Kesimpta PenOfatumumab13$110,778
Emgality SyringeGalcanezumab-Gnlm123$106,023
Ajovy AutoinjectorFremanezumab-Vfrm77$60,025
Pregabalin1,069$55,134
Memantine Hcl1,125$29,774
Gabapentin1,677$28,492
Levetiracetam664$24,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$1,776$1,148,716897 claims
PfizerNurtec Odt, Eliquis$1,045$679,721427 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$194,299104 claims
Neurocrine Biosciences, Inc.Ingrezza$69$186,25717 claims
CSL BehringHizentra$20$123,58424 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$41$8,92177 claims
UCB, Inc.Nayzilam$388$8,49313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Saint Cloud

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →